$16.53
-0.82 (-4.73%)
Theravance, Inc. (NASDAQ:THRX)
CAPS Rating:
A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.
RSS Headlines
Fool UK